版本:
中国

BRIEF-Syros says on track to begin Phase 1 trial of SY-1365 in Q2

April 3 Syros Pharmaceuticals Inc:

* Syros Pharmaceuticals Inc - new data demonstrate SY-1365 inhibits tumor growth in In Vivo models of triple negative breast cancer

* Syros Pharmaceuticals Inc - new data demonstrate sy-1365 inhibits tumor growth in in vivo models of triple negative breast cancer

* Syros Pharma - new data show sy-1365 has anti-proliferative activity in additional cancer cells, including ovarian and small cell lung cancers

* Syros Pharmaceuticals Inc - on track to begin a Phase 1 clinical trial of SY-1365 in Q2 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐